Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients

NCT07366372 | Completed

• 1 other identifier: 36264MD73/4/23
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to assess effectiveness of a taurolidine based lock solution in preventing the infections of central venous catheter (CVC) in intensive care unit (ICU) cases.

Conditions

Taurolidine; Lock Solution; Prevention; Central Venous Catheter Infection; Intensive Care Unit

Outcome Measures

Primary Outcomes (1)

• Positive bacterial growth

  Positive bacterial growth of a swab was recorded.

  30 days after the procedure

Secondary Outcomes (4)

• Assessment of catheter-related bloodstream infection

  30 days after the procedure

• Assessment of central venous catheter infection

  30 days after the procedure

• Lenght of intensive care unit stay

  30 days after the procedure

• Incidence of mortality

  30 days after the procedure

Study Arms (3)

Group I

PLACEBO COMPARATOR

Central venous catheters (CVCs) were locked with 2ml saline as a control group.

Drug: Saline

Group II

EXPERIMENTAL

Central venous catheters (CVCs) were locked with 2ml of a solution comprising tigecycline 5mg/ml and heparin 500 IU/ml.

Drug: Tigecycline and heparin

Group III

EXPERIMENTAL

Central venous catheters (CVCs) were locked with 2ml of a solution containing taurolidine-citrate-heparin (1.35% taurolidine, 4% citrate, and 500 IU/ml heparin).

Drug: Taurolidine-citrate-heparin

Interventions

Taurolidine-citrate-heparin DRUG

Central venous catheters (CVCs) were locked with 2ml of a solution containing taurolidine-citrate-heparin (1.35% taurolidine, 4% citrate, and 500 IU/ml heparin).

Group III

Saline DRUG

Central venous catheters (CVCs) were locked with 2ml saline as a control group.

Group I

Tigecycline and heparin DRUG

Central venous catheters (CVCs) were locked with 2ml of a solution comprising tigecycline 5mg/ml and heparin 500 IU/ml.

Group II

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \> 21 years.
• Both genders.
• Patients admitted to the intensive care unit (ICU) requiring central venous catheter insertion.

You may not qualify if:

• Cases with active infections, hemorrhage or bleeding disorders, infections within insertion place.
• History of allergy to taurolidine, tigecycline, heparin, and citrate.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location

MeSH Terms

Interventions

Sodium Chloride; Tigecycline; Heparin

Intervention Hierarchy (Ancestors)

Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds; Tetracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Glycosaminoglycans; Polysaccharides; Carbohydrates

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer of Anesthesiology, Intensive Care and Pain Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: January 17, 2026
• First Posted: January 26, 2026
• Study Start: May 1, 2023
• Primary Completion: November 1, 2024
• Study Completion: November 1, 2024
• Last Updated: January 26, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)